AUTH:"Azbekyan A" - Search results

Search results

1-3 of 3 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
Lobo SM, Plantefève G, Nair G, Joaquim Cavalcante A, Franzin de Moraes N, Nunes E, Barnum O, Berdun Stadnik CM, Lima MP, Lins M, Hajjar LA, Lipinski C, Islam S, Ramos F, Simon T, Martinot JB, Guimard T, Desclaux A, Lioger B, [...] Morelot-Panzini C
EClinicalMedicine, 68:102383, 03 Jan 2024
Cited by: 3 articles | PMID: 38545090 | PMCID: PMC10965409
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Oral 20-Hydroxyecdysone (BIO101), a MAS Receptor Activator,Reduces the Combined Proportion of Respiratory Failures or Early Deaths in Adults with Severe COVID-19. Findings of a Randomized, Placebo-Controlled, Phase 2/3 Trial (COVA)
Lobo SM, Plantefeve G, Nair G, Cavalcante Aj, Moraes N, Nunes EP, Barnum O, Stadnik CMB, Lima Mp, Lins M, Hajjar LA, Lipinski C, Islam S, Ramos F, Simon T, Martinot J, Guimard T, Desclaux A, Lioger B, [...] Morelot-Panzini C
SSRN, 05 Jul 2023
Cited by: 0 articles | PPR: PPR686595
Add to export list Preprint
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W, Chabane M, Tourette C, Azbekyan A, Morelot-Panzini C, Hajjar LA, Lins M, Nair GB, Whitehouse T, Mariani J, Latil M, Camelo S, Lafont R, Dilda PJ, Veillet S, Agus S
Trials, 22(1):42, 11 Jan 2021
Cited by: 11 articles | PMID: 33430924 | PMCID: PMC7797700
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-3 of 3 results

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.

Oral 20-Hydroxyecdysone (BIO101), a MAS Receptor Activator,Reduces the Combined Proportion of Respiratory Failures or Early Deaths in Adults with Severe COVID-19. Findings of a Randomized, Placebo-Controlled, Phase 2/3 Trial (COVA)

Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.

Partnerships & funding